AARD - Aardvark Therapeutics Inc.

6.11
0.390   6.383%

Share volume: 181,776
Last Updated: 05-12-2026
Pharmaceutical Products/Pharmaceutical Preparations: 0.10%

PREVIOUS CLOSE
CHG
CHG%
$5.72
0.39
0.07%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
46%
Profitability 35%
Dept financing 28%
Liquidity 50%
Performance 60%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
12.32%
1 Month
52.37%
3 Months
-49.50%
6 Months
-43.74%
1 Year
-39.74%
2 Year
-57.30%
Key data
Stock price
$6.11
P/E Ratio 
0.00
DAY RANGE
$5.56 - $6.17
EPS 
-$3.26
52 WEEK RANGE
$3.35 - $17.94
52 WEEK CHANGE
-$30.09
MARKET CAP 
82.246 M
YIELD 
N/A
SHARES OUTSTANDING 
21.816 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
N/A
AVERAGE 10 VOLUME 
$126,015
AVERAGE 30 VOLUME 
$147,433
Company detail
CEO: Tien-Li Lee
Region: US
Website: aardvarktherapeutics.com
Employees: 18
IPO year: 2025
Issue type:
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

We are a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. We were incorporated in Delaware on May 17, 2017. Our principal executive offices are located at 4370 La Jolla Village Drive, Suite 1050, San Diego, CA. We have one wholly-owned subsidiary, Artisan Therapeutics, Inc., incorporated in Delaware in October 2024.

Recent news